drugset
drugset / Trial / NCT01853826

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

NCT01853826 ↗

Phase 3 Completed 481 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of afatinib (Giotrif) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s) and have never been treated with an EGFR-TKI

Timeline

Start
2013-07-17
Primary completion
2024-03-06
Completion
2024-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Afatinib Small molecule 20 mg Oral
Subject Afatinib Small molecule 30 mg Oral
Subject Afatinib Small molecule 40 mg Oral

Indications

non-small cell lung carcinoma